Maria de Lourdes de Sousa Maia

Maria de Lourdes de Sousa Maia

Auto-generated profile, based on publicly available information

Maria de Lourdes de Sousa Maia

Departamento de Assuntos Médicos, Estudos Clínicos e Vigilância Pós-Registro (DEAME), Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos), Fundação Oswaldo Cruz, Rio de Janeiro 21040-360, Brazil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PBPaul Bastard
Paul Bastard
EMEleftherios Michailidis
Eleftherios Michailidis
HHHans-Heinrich Hoffmann
Hans-Heinrich Hoffmann
MCMarwa Chbihi
Marwa Chbihi
TVTom Le Voyer
Tom Le Voyer
JCJean-Laurent Casanova
Jean-Laurent Casanova
Yellow fever virus (YFV) live attenuated vaccine can, in rare cases, cause life-threatening disease, typically in patients with no previous history of severe viral illness. Autosomal recessive (AR) complete IFNAR1 deficiency was reported in one 12-yr-old patient. Here, we studied seven other previously healthy patients aged 13 to 80 yr with unexplained life-threatening YFV vaccine–associated disease. One 13-yr-old patient had AR complete IFNAR2 deficiency. Three other patients vaccinated at the ages of 47, 57, and 64 yr had high titers of circulating auto-Abs against at least 14 of the 17 individual type I IFNs. These antibodies were recently shown to underlie at least 10% of cases of life-threatening COVID-19 pneumonia. The auto-Abs were neutralizing in vitro, blocking the protective effect of IFN-α2 against YFV vaccine strains. AR IFNAR1 or IFNAR2 deficiency and neutralizing auto-Abs against type I IFNs thus accounted for more than half the cases of life-threatening YFV vaccine-associated disease studied here. Previously healthy subjects could be tested for both predispositions before anti-YFV vaccination.

15 July 2014 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ACAna Carolina Campi-Azevedo
Ana Carolina Campi-Azevedo
PEPaula de Almeida Estevam
Paula de Almeida Estevam
JCJordana Grazziela Alves Coelho-dos-Reis
Jordana Grazziela Alves Coelho-dos-Reis
VPVanessa Peruhype-Magalhães
Vanessa Peruhype-Magalhães
GVGabriela Villela-Rezende
Gabriela Villela-Rezende
OMOlindo Martins-filho
Olindo Martins-filho
The live attenuated 17DD Yellow Fever vaccine is one of the most successful prophylactic interventions for controlling disease expansion ever designed and utilized in larger scale. However, increase on worldwide vaccine demands and manufacturing restrictions urge for more detailed dose sparing studies. The establishment of complementary biomarkers in addition to PRNT and Viremia could support a secure decision-making regarding the use of 17DD YF vaccine subdoses. The present work aimed at comparing the serum chemokine and cytokine kinetics triggered by five subdoses of 17DD YF Vaccine.

4 January 2018 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
MCMarisa Boff Costa
Marisa Boff Costa
PPPaulo Dornelles Picon
Paulo Dornelles Picon
GSGuilherme Becker Sander
Guilherme Becker Sander
HCHugo Nodarse Cuni
Hugo Nodarse Cuni
CSCarmen Valenzuela Silva
Carmen Valenzuela Silva
PSPedro Lopez Saura
Pedro Lopez Saura
Several countries have used pegylation technology to improve the pharmacokinetic properties of essential drugs. Recently, a novel interferon alfa-2b protein conjugated to four-branched 12 kDa polyethylene glycol molecules was developed jointly between Cuba and Brazil. The aim of this study was to compare the pharmacokinetic properties of BIP48 (pegylated interferon alfa-2b from Bio-Manguinhos/Fiocruz, Brazil) to those of PEGASYS® (commercially available pegylated interferon alfa-2a from Roche Pharmaceutical). This phase I, single-centre, randomized, double-blind crossover trial enrolled 31 healthy male volunteers aged 19 to 35 who were allocated to two stages, either side of a 5-week wash-out period, with each arm lasting 14 consecutive days after subcutaneous administration of 180 μg of one formulation or the other (study or comparator). The main outcome variable was serum pegylated interferon concentrations in 15 samples collected during the course of the study and tested using an enzyme immunoassay. There were no differences between formulations in terms of magnitude or absorption parameters. Analysis of time parameters revealed that BIP48 remained in the body significantly longer than PEGASYS® (Tmax: 73 vs. 54 h [p = 0.0010]; MRT: 133 vs. 115 h [p = 0.0324]; ke: 0.011 vs. 0.013 h(−1) [p = 0.0153]; t1/2: 192 vs. 108 h [p = 0.0218]). BIP48 showed the expected pharmacokinetic profile for a pegylated product with a branched molecular structure. Compared to PEGASYS®, the magnitude absorption was similar, but time parameters were consistent with slower elimination. Further studies should be conducted to evaluate the clinical implications of these findings. A phase II-III repeated-dose clinical trial is ongoing to study these findings in patients with chronic hepatitis C virus infection. This study is registered on the ClinicalTrials.gov platform (accession number NCT01889849 ). This trial was retrospectively registered in June 2013.

1 January 2023 in Cadernos de Saude Publica
Verified
Journal Article
Open access
AHAkira Homma
Akira Homma
MMMaria de Lourdes de Sousa Maia
Maria de Lourdes de Sousa Maia
IAIsabel Cristina Alencar de Azevedo
Isabel Cristina Alencar de Azevedo
IFIsabella Lira Figueiredo
Isabella Lira Figueiredo
LGLuciano Bezerra Gomes
Luciano Bezerra Gomes
DCDaniel Bruschi Cardoso
Daniel Bruschi Cardoso
O declínio global das coberturas vacinais levou a Organização Mundial da Saúde (OMS), em 2019, a definir a hesitação vacinal como uma das dez maiores ameaças mundiais à saúde pública. No Brasil, a queda da cobertura vacinal teve início em 2012, acentuando-se a partir de 2016, e sendo agravada pela pandemia de COVID-19. O alerta da baixa cobertura vacinal vem acompanhado pela reintrodução de doenças imunopreveníveis como o sarampo. O retorno de doenças até então eliminadas, como a poliomielite, pode agravar a crise sanitária ainda em curso. Mesmo sendo reconhecido como um dos mais efetivos programas de imunizações do mundo e dos esforços permanentes, o Programa Nacional de Imunizações enfrenta um cenário extremamente adverso no que tange às coberturas vacinais. Este artigo descreve o Projeto pela Reconquista das Altas Coberturas Vacinais (PRCV) e a estratégia de trabalhar na ponta do sistema, executada nos territórios, que vem sendo implementada desde 2021 e já começa a apresentar resultados promissores. O PRCV foi organizado em três eixos temáticos com atuação compartilhada e ações específicas, a saber: vacinação; sistemas de informação; comunicação e educação. Os resultados já alcançados permitem afirmar que é possível conseguir a reversão das baixas coberturas vacinais, a partir da articulação de ações estruturais e interinstitucionais, com o fortalecimento das políticas públicas e desenvolvimento de medidas de curto, médio e longo prazos. Os fatores mais potentes do PRCV são sua abordagem junto aos profissionais da ponta, o pacto social pela vacinação, e a estruturação de redes locais de apoio às imunizações.

1 January 2020 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
POPatricia Mouta Nunes de Oliveira
Patricia Mouta Nunes de Oliveira
LLLetícia Kegele Lignani
Letícia Kegele Lignani
DCDeborah Araújo da Conceição
Deborah Araújo da Conceição
PFPaula Molinari Cardoso de Mello Farias
Paula Molinari Cardoso de Mello Farias
PTPaulo Roberto Gomes Takey
Paulo Roberto Gomes Takey
LCLuiz Antonio Bastos Camacho
Luiz Antonio Bastos Camacho
A vacinação é uma das ações mais efetivas para proteger o indivíduo e a população contra doenças imunopreveníveis. Vacinas são produtos seguros e eficazes, porém, como qualquer outro medicamento, podem causar eventos adversos, que ganham maior visibilidade na medida em que as doenças são controladas, eliminadas ou erradicadas. Este trabalho analisou as ações de vigilância de eventos adversos pós-vacinação (EAPV) com base em dados da literatura científica e sites de programas de imunizações, agências reguladoras e de saúde, além da expertise dos autores nas áreas de imunizações e farmacovigilância. Com o aumento do número de vacinas no calendário básico e a ampliação do acesso da população, tornou-se fundamental o estabelecimento de um sistema eficiente de vigilância de EAPV no Brasil. Entretanto, a subnotificação de casos no Brasil e em outros países dificulta a detecção de EAPV, principalmente os raros. Informações sempre atualizadas sobre o benefício/risco das vacinas permitem que programas de imunizações deem respostas rápidas e claras aos rumores de EAPV. Isso garante a confiabilidade no sistema, ainda mais diante do crescente movimento antivacinista e a influência cada vez maior das mídias sociais na opinião pública.

1 March 2015 in Contemporary Clinical Trials
Verified
Journal Article
Open access
RMReinaldo de Menezes Martins
Reinaldo de Menezes Martins
BCBirute Curran
Birute Curran
MMMaria de Lourdes Sousa Maia
Maria de Lourdes Sousa Maia
MRMaria das Graças Tavares Ribeiro
Maria das Graças Tavares Ribeiro
LCLuiz Antonio Bastos Camacho
Luiz Antonio Bastos Camacho
DZDarin Zehrung
Darin Zehrung
This study aimed to determine if immunogenicity to measles-mumps-rubella vaccine delivered to infants via a disposable-syringe jet injector (DSJI) was non-inferior to that administered by needle and syringe (NS). Vaccination safety was evaluated, as were the use, performance, and acceptability of each delivery method. The DSJI was the PharmaJet 2009 generation-1 device (G1) and the vaccine was measles-mumps-rubella vaccine from Bio-Manguinhos. Five hundred eighty-two healthy Brazilian infants were randomized to receive vaccine via G1 or NS. Seroconversion rates against measles and mumps viruses in the G1 treatment group did not meet non-inferiority criteria when compared with the NS group; however, responses in the G1 group to rubella virus were non-inferior to those of NS vaccinees. Most adverse events were mild or moderate. Crying after injection was more frequent in the NS group, and local skin reactions were more common in the G1 group. Five serious adverse events were judged causally unrelated to treatment and all resolved. Parents/guardians expressed a strong preference for G1 over NS for their children. Vaccinators found the G1 easy to use but noted incomplete vaccine delivery in some cases. Although the G1 has been superseded by an updated device, our results are important for the continued improvement and evaluation of DSJIs, which have the potential to overcome many of the challenges and risks associated with needle-based injections worldwide. Recommendations for future DSJI clinical studies include rigorous training of vaccinators, quantitative measurement of wetness on the skin following injection, and regular monitoring of device and vaccinator performance.